Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Sign Up to like & getrecommendations! Published in 2018 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2018.06.017
Abstract: OBJECTIVE To determine the efficacy of dalantercept, a soluble ALK1 inhibitor receptor fusion protein, in patients with persistent or recurrent ovarian carcinoma and related malignancies. METHODS Eligibility criteria included measurable disease, 1-2 prior cytotoxic regimens… read more here.
Keywords: evaluation dalantercept; phase evaluation; treatment; gynecologic oncology ... See more keywords